Logo image of NGEN.CA

NERVGEN PHARMA CORP (NGEN.CA) Stock Fundamental Analysis

Canada - TSX-V:NGEN - CA64082X2032 - Common Stock

3.6 CAD
-0.05 (-1.37%)
Last: 9/18/2025, 7:00:00 PM
Fundamental Rating

2

Overall NGEN gets a fundamental rating of 2 out of 10. We evaluated NGEN against 34 industry peers in the Pharmaceuticals industry. The financial health of NGEN is average, but there are quite some concerns on its profitability. NGEN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NGEN had negative earnings in the past year.
NGEN had a negative operating cash flow in the past year.
NGEN had negative earnings in each of the past 5 years.
NGEN had a negative operating cash flow in each of the past 5 years.
NGEN.CA Yearly Net Income VS EBIT VS OCF VS FCFNGEN.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -161.68%, NGEN is doing worse than 91.18% of the companies in the same industry.
NGEN has a worse Return On Equity (-1843.02%) than 88.24% of its industry peers.
Industry RankSector Rank
ROA -161.68%
ROE -1843.02%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NGEN.CA Yearly ROA, ROE, ROICNGEN.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NGEN.CA Yearly Profit, Operating, Gross MarginsNGEN.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

There is no outstanding debt for NGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NGEN.CA Yearly Shares OutstandingNGEN.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
NGEN.CA Yearly Total Debt VS Total AssetsNGEN.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

2.2 Solvency

NGEN has an Altman-Z score of -1.55. This is a bad value and indicates that NGEN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.55, NGEN is doing worse than 67.65% of the companies in the same industry.
There is no outstanding debt for NGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.55
ROIC/WACCN/A
WACCN/A
NGEN.CA Yearly LT Debt VS Equity VS FCFNGEN.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

NGEN has a Current Ratio of 1.06. This is a normal value and indicates that NGEN is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.06, NGEN is not doing good in the industry: 76.47% of the companies in the same industry are doing better.
NGEN has a Quick Ratio of 1.06. This is a normal value and indicates that NGEN is financially healthy and should not expect problems in meeting its short term obligations.
NGEN has a Quick ratio (1.06) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 1.06
NGEN.CA Yearly Current Assets VS Current LiabilitesNGEN.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

NGEN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.54%.
EPS 1Y (TTM)5.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 50.10% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.85%
EPS Next 2Y24.03%
EPS Next 3Y12.47%
EPS Next 5Y50.1%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NGEN.CA Yearly Revenue VS EstimatesNGEN.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 200M 400M 600M
NGEN.CA Yearly EPS VS EstimatesNGEN.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NGEN. In the last year negative earnings were reported.
Also next year NGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NGEN.CA Price Earnings VS Forward Price EarningsNGEN.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NGEN.CA Per share dataNGEN.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

NGEN's earnings are expected to grow with 12.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.03%
EPS Next 3Y12.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NERVGEN PHARMA CORP

TSX-V:NGEN (9/18/2025, 7:00:00 PM)

3.6

-0.05 (-1.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-26 2025-08-26/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners0.06%
Inst Owner ChangeN/A
Ins Owners2.36%
Ins Owner ChangeN/A
Market Cap263.81M
Analysts80
Price Target7.24 (101.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.72%
Min EPS beat(2)-51.43%
Max EPS beat(2)33.99%
EPS beat(4)2
Avg EPS beat(4)-3.86%
Min EPS beat(4)-51.43%
Max EPS beat(4)33.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-19.55%
PT rev (3m)42.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)37.5%
EPS NY rev (1m)18.87%
EPS NY rev (3m)18.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 189.86
P/tB 281.1
EV/EBITDA N/A
EPS(TTM)-0.39
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0
BVpS0.02
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -161.68%
ROE -1843.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.06
Quick Ratio 1.06
Altman-Z -1.55
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)38.62%
Cap/Depr(5y)46.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
EPS Next Y2.85%
EPS Next 2Y24.03%
EPS Next 3Y12.47%
EPS Next 5Y50.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.72%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.41%
OCF growth 3YN/A
OCF growth 5YN/A